Ys Biopharma Co Stock Net Income

YS Stock   0.43  0.05  13.16%   
YS Biopharma Co fundamentals help investors to digest information that contributes to YS Biopharma's financial success or failures. It also enables traders to predict the movement of YS Biopharma Stock. The fundamental analysis module provides a way to measure YS Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to YS Biopharma stock.
Net Income is likely to drop to about (275.3 M) in 2024. Net Income Common Stock is likely to drop to about (409.3 M) in 2024.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

YS Biopharma Net Income Analysis

YS Biopharma's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

YS Biopharma Net Income

(275.27 Million)

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis

Current YS Biopharma Net Income

    
  (145.48 M)  
Most of YS Biopharma's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, YS Biopharma Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

YS Biopharma Net Income Historical Pattern

Today, most investors in YS Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various YS Biopharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's net income growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of YS Biopharma net income as a starting point in their analysis.
   YS Biopharma Net Income   
       Timeline  
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

YS Biopharma Accumulated Other Comprehensive Income

Accumulated Other Comprehensive Income

(50.26 Million)

At this time, YS Biopharma's Accumulated Other Comprehensive Income is comparatively stable as compared to the past year.
Based on the recorded statements, YS Biopharma Co reported net income of (145.48 Million). This is 142.63% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 125.48% higher than that of the company.

YS Biopharma Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses YS Biopharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of YS Biopharma could also be used in its relative valuation, which is a method of valuing YS Biopharma by comparing valuation metrics of similar companies.
YS Biopharma is currently under evaluation in net income category among related companies.

YS Biopharma Fundamentals

About YS Biopharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze YS Biopharma Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of YS Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of YS Biopharma Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2024
Net Income-255.1 M-275.3 M
Net Income Common Stock-379.3 M-409.3 M
Net Income to Non Controlling Interests158.7 M138.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether YS Biopharma is a strong investment it is important to analyze YS Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact YS Biopharma's future performance. For an informed investment choice regarding YS Biopharma Stock, refer to the following important reports:
Check out YS Biopharma Piotroski F Score and YS Biopharma Altman Z Score analysis.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for YS Biopharma Stock analysis

When running YS Biopharma's price analysis, check to measure YS Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy YS Biopharma is operating at the current time. Most of YS Biopharma's value examination focuses on studying past and present price action to predict the probability of YS Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move YS Biopharma's price. Additionally, you may evaluate how the addition of YS Biopharma to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
CEOs Directory
Screen CEOs from public companies around the world
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Bonds Directory
Find actively traded corporate debentures issued by US companies
Transaction History
View history of all your transactions and understand their impact on performance
Is YS Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of YS Biopharma. If investors know YS Biopharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about YS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.56)
Revenue Per Share
5.159
Quarterly Revenue Growth
(0.50)
Return On Assets
(0.12)
Return On Equity
(0.62)
The market value of YS Biopharma is measured differently than its book value, which is the value of YS Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of YS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is YS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because YS Biopharma's market value can be influenced by many factors that don't directly affect YS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between YS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if YS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, YS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.